OX2 News and Updates
Featured Stories
All Stories
OX2 Reaches Recommended Phase 2 Dose Milestone in Pediatric Brain Tumor Trial
Trial advances forward with no dose-limited toxicities observed to date. MINNEAPOLIS (May 1, 2026) – OX2 Therapeutics, Inc. today announces it has reached its Recommended Phase 2 Dose (RP2D) in its ongoing clinical trial evaluating ARL200 + GBM6-AD Vaccine in…
Vaccine Trial Launched to Fight Pediatric Brain Cancer
University of Minnesota researchers have launched a promising vaccine trial targeting childhood brain cancer, offering hope to improve survival and quality of life for young patients.
New Treatment for Central Nervous System Tumors Enters Phase I Clinical Trials
OX2 Therapeutics has begun a Phase I clinical trial for a first-of-its-kind immunotherapy targeting aggressive brain tumors, aiming to boost the immune system and improve outcomes for patients.
FDA Grants IND Approval to OX2 Therapeutics to Initiate Phase I Clinical Trial of Its Peptide Checkpoint Modulator for Patients with CNS Tumors
FDA Grants IND Approval to OX2 Tx to Proceed in a Phase I Clinical trial of its Peptide Checkpoint Inhibitor for Patients with Central Nervous System Tumors MINNEAPOLIS, MN, USA, June 8, 2020 /EINPresswire.com/ — OX2 Therapeutics, Inc, a privately held Minneapolis…